share_log

Gilead Sciences To Present EVOKE-01 Study Results In Metastatic NSCLC At An Oral Session At ASCO 2024

Benzinga ·  May 31 20:16

– Simultaneously Published by the Journal of Clinical Oncology –

Gilead Sciences, Inc. (NASDAQ:GILD) today announced detailed results from the Phase 3 EVOKE-01 study that will be presented during an oral session (Abstract #LBA8500) today (2:45-5:45pm CT) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The results were also published simultaneously in the Journal of Clinical Oncology. The company previously announced that the study did not meet the primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC).

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment